AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

Author's Avatar
Sep 22, 2021

AbCellera (Nasdaq: ABCL) and Everest+Medicines+Limited (HKEX 1952.HK, “Everest”) announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest. The partnership will help to expand Everest’s portfolio of novel medicines across multiple indications, with the initial programs focusing on targets in oncology.